Sun Pharma closes InSite Vision acquisition

MUMBAI — Sun Pharmaceutical Industries announced Tuesday that it had completed its acquisition of InSite Vision, which is now an indirect wholly owned subsidiary of the company. Sun Pharma is the fifth largest specialty generics company in the world. 

 

As part of the merger, anyone with outstanding common stock in InSite can redeem it for $0.35 per share.